Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures

Cara L Croft, Matthew A Wade, Ksenia Kurbatskaya, Pavlina Mastrandreas, Martina M Hughes, Emma C Phillips, Amy M Pooler, Michael S Perkinton, Diane P Hanger and Wendy Noble

The spatiotemporal transmission of pathological tau in the brain is characteristic of Alzheimer's disease. Release of both soluble and abnormal tau species from healthy neurons is increased upon stimulation of neuronal activity. It is not yet understood whether the mechanisms controlling soluble tau release from healthy neurons is the same as those involved in the spread of pathological tau species. To begin to understand these events, we have studied tau distribution and release using organotypic brain slice cultures. The slices were cultured from postnatal wild-type and 3xTg-AD mice for up to 1 month. Tau distribution in subcellular compartments was examined by western blotting, and tau release into culture medium was determined using a sensitive sandwich ELISA. We show here that 3xTg-AD cultures have an accelerated development of pathological tau abnormalities including the redistribution of tau to synaptic and membrane compartments. The 3xTg-AD slice cultures show elevated basal tau release relative to total tau when compared with wild-type cultures. However, tau release from 3xTg-AD slices cannot be further stimulated when neuronal activity is increased with potassium chloride. Moreover, we report that there is an increased pool of dephosphorylated membrane-associated tau in conditions where tau release is increased. These data suggest that there may be differential patterns of tau release when using integrated slice culture models of wild-type and transgenic mouse brain, although it will be important to determine the effect of tau overexpression for these findings. These results further increase our knowledge of the molecular mechanisms underlying tau release and propagation in neurodegenerative tauopathies.

Cell Death and Disease (2017) 8, e2671; doi:10.1038/cddis.2017.97; published online 16 March 2017

The characteristic progressive accumulation of tau pathology in affected brain regions during the development of Alzheimer's disease (AD) is believed to result from the spread of aggregated tau along anatomically connected pathways. Restricted expression of transgenic tau in the entorhinal cortex results in both local accumulation of aggregated tau resulting in neuron loss, and the trans-synaptic spread of tau aggregates to more distal regions of the brain. The spread of pathological tau and the extent of neurotoxicity in this model is also further accelerated by the presence of Aβ. The precise mechanisms of tau spread are not yet fully understood, however, the species of tau involved appears to be critical, as are the extracellular vesicles such as exosomes in which tau can be compartmentalised in different phosphorylation states. Synaptic connectivity, rather than the proximity of neurons, appears to be critical for tau propagation, and therefore understanding the routes by which tau is released from neurons is important for elucidating how pathological tau spreads through the brain in AD and other tauopathies.

We previously showed that tau release from neurons is a physiological process that is stimulated by neuronal activity in cultured rat neurons. Similar findings have since been reported in vivo. The relationship between tau release and neuronal activity appears to be bi-directional since both extracellulartau and Aβ feedback to neurons to perpetuate further tau release. Released endogenous tau is reported to be released free in a dephosphorylated full-length form or as N-terminally truncated fragments. A small proportion of tau released under these conditions is associated with exosomes, plasma membrane-derived vesicles. Particularly when tau is exogenously expressed or in a highly phosphorylated misfolded state, it is released from cells in association with exosomes and can be highly phosphorylated. The apparent discrepancies in these findings raise the question of whether physiological species of soluble tau are released via the same mechanisms as are involved in the propagation of pathological tau forms.

To investigate these mechanisms further, we have examined tau release from organotypic brain slice cultures prepared from wild-type and 3xTg-AD mice. Recent publications have highlighted the utility of using organotypic nervous tissue slices for modelling neurodegenerative diseases. Organotypic brain slice cultures from transgenic models of AD develop some of the main molecular hallmarks of human disease including ‘plaque-like’ depositions when prepared from APP transgenic mice, and abnormally phosphorylated tau when tau overexpressing mice are used. Moreover, these models can be used to examine the cellular mechanisms underlying AD including Aβ-mediated synaptotoxicity.

We show here for the first time that organotypic brain slices cultured from postnatal 3xTg-AD pups show accelerated development of AD-like molecular pathology. Notably,
3xTg-AD slices exhibit increased basal tau release relative to total tau amounts when compared with wild-type slices. Stimulation of neuronal activity with KCl increased tau release from wild-type slices, in line with reports in primary neurons and in vivo, whereas the extent of tau release from 3xTg-AD slices was unchanged by KCl stimulation. In both wild-type and 3xTg-AD slices, there was a marked correlation between the amount of dephosphorylated tau present at membranes and the extent of tau release, in keeping with reports that tau localisation is important for its propagation. Taken together, these results suggest that the mechanisms governing the release of physiological and pathological forms of tau may be differentially regulated by neuronal stimulation. These findings might support the existence of functionally distinct pools of extracellular tau with physiological tau contributing to neuronal signalling in a healthy brain environment and pathological tau driving the spread of tau pathology in diseased brain. However, potential effects of overexpression on tau localisation and release must be taken into account when interpreting the results of this work as it is possible that saturation of signalling and release must be taken into account when interpreting the results of this work as it is possible that saturation of

**Results**

**Organotypic brain slice cultures from 3xTg-AD mice recapitulate molecular phenotypes of aged brain.** We first determined the extent to which organotypic brain slice cultures prepared from 3xTg-AD mice recapitulate the neurodegenerative molecular changes that develop in vivo and in human AD brain. Cortical extracts from 3xTg-AD mice showed overexpression of total tau, as expected on the basis of human tau overexpression (Figure 1a). At the ages examined here, no significant increases in tau phosphorylation at CP13 (Ser202) or PHF1 (Ser396/404) were observed, in line with previous reports.

However, an increased abundance of sarkosyl-insoluble tau was apparent in 12-month-old 3xTg-AD cortex (Figure 1b), as described previously. The 3xTg-AD cortex also showed a progressive accumulation of total APP and Aβ1-42 relative to age-matched wild-type controls (Figure 2a), similar to that previously described by Oddo et al.

Cultured brain slices from 3xTg-AD mice were characterised by an accumulation of total tau (Figure 1c), similar to that observed in aged brain. 14–28 days in vitro (DIV) slices also displayed significant increases in tau phosphorylation at Ser202 and Ser396/404 relative to wild-type controls, with these epitopes being hyperphosphorylated in AD brain. These data suggest accelerated disease-associated tau phosphorylation in cultured brain slices in comparison to in vivo aged 3xTg-AD brain, as previously reported for other tau transgenic lines. In support of this, an accumulation of approximately 64 kDa tau (Figure 1c) was apparent in 3xTg-AD slices at 21 DIV (Figure 1d). Such higher molecular weight tau species precede the accumulation of sarkosyl-insoluble material in several tau transgenic lines. Tau in 3xTg-AD slices was not limited to axons but showed a somatodendritic appearance, characteristic of tau localisation in AD (Figure 1e). 3xTg-AD brain slice cultures also showed increased expression of APP at 14 DIV and over-production of Aβ1-42 when aged for 28 DIV (Figure 2b). It is possible that the increased APP observed in slice cultures at relatively early DIV represents a synaptic compensation response, similar to that recently reported during AD progression. We have previously shown that sustained culture over months allows the development of small diffuse plaques in other APP transgenic lines.

**Basal tau release from brain slice cultures**

Synaptosomes were prepared from mouse brain and slice cultures to allow examination of protein association with synaptic compartments. We have previously demonstrated the enrichment of synaptic proteins in the synaptosomal fraction relative to the non-synaptosomal fraction using this protocol. No changes in post-synaptic markers, even in the oldest 3xTg-AD animals examined here (12 months of age, Figure 3a), were detected in synaptosomes isolated from 3xTg-AD and wild-type cortex. This is in keeping with previous analysis reporting no alterations in synapse density or synaptic contact area in 13-month-old 3xTg-AD mice. Interestingly, when synaptosome preparations were immunoblotted with antibodies against tau and APP, the results suggested a transient trend towards upregulation of tau in the synaptic compartment in young (1–2-month-old) mice that was lost with aging (Figure 3b). APP was also somewhat increased in synapses; the increases at 1, 2 and 9 months being significantly different when compared with wild-type (Figure 3b).

In 3xTg-AD slices, no reductions in PSD-95 and synaptic-physin amounts were apparent in immunoblotted synaptosomes, suggesting that synapses remaining in these cultures are relatively healthy and intact (Figure 3c). However, these slice cultures also showed a transient redistribution of tau into synaptic compartments in 14 DIV slices relative to controls (Figure 3d). This likely represents a redistribution rather than passive process as tau levels in the synapses are not sustained, unlike the levels of tau overexpression observed in 3xTg-AD slices that are only significantly increased from wild type from 21 DIV (Figure 1c). Such redistribution of tau to synapses was recently shown to be an important biological correlate of dementia in AD, and suggests that some AD-relevant changes may be recapitulated in this slice culture model. There were no changes in APP abundance at synapses over 28 days in culture (Figure 3d). Again, the abundance of APP at synapses does not appear to be associated with APP overexpression in these slices since total APP was significantly elevated relative to wild type at 14 DIV, at which time there was no increase in synaptic APP.

3xTg-AD slice cultures show increased levels of basal tau release. We next assessed basal tau release from 3xTg-AD slice cultures in comparison with that from wild-type controls. Total amounts of tau released into medium over a period of 30 min were measured using an in-house total tau ELISA that uses two commercially available tau antibodies with epitopes in the middle region (BT2) and C-terminal half (Dako) of tau. Intracellular tau amounts were determined in the same cultures by immunoblotting, as described above. The amounts of tau detected in culture medium were then normalised to amounts of intracellular tau in the same sample to control for the effects of tau overexpression in the 3xTg-AD.
slices and to allow the proportion of total tau released from slices to be determined. In addition, the amount of lactate dehydrogenase (LDH) released into the media from the same slices was measured to ensure that changes in tau release are not a result of increased cell death. The LDH content in culture medium was calculated as a proportion of the total LDH in the slice culture lysates plus that measured in medium.

Figure 1 Organotypic brain slice cultures from 3xTg-AD mice show accelerated development of tau abnormalities. Representative western blots of cortical brain lysates prepared from 1-, 2-, 4-, 9- and 12-month-old wild-type and 3xTg-AD mice, probed with antibodies against tau (both non-phosphorylated and phosphorylated), PHF1 (phospho-Ser396/404), Tau-1 (dephospho-Ser199/202/Thr205) and CP13 (phospho-Ser202). Blots were also probed with an antibody against β-actin as a loading control. Bar charts show amounts of total tau relative to β-actin, and phospho-tau as a proportion of total tau, n=3. (b) Sarkosyl-insoluble tau was isolated from 4- and 12-month-old wild-type (WT) and 3xTg-AD mice. Western blots show tau in the low-speed supernatant and sarkosyl-insoluble fraction. The amount of sarkosyl-insoluble relative to total tau in low-speed supernatants is shown in the bar chart, n=3. (c) Lysates were prepared from wild-type and 3xTg-AD brain slice cultures at 14, 21 and 28 days in vitro (DIV), n=12. Blots were probed with total tau and phosphorylation-dependent tau antibodies. An antibody against β-actin was used as a loading control. Bar charts show amounts of total tau relative to β-actin, and phospho-tau as a proportion of total tau (Dako), n=12. (d) Bar chart shows the amount of 64 kDa tau in wild-type and 3xTg-AD brain slice cultures as detected by the total tau antibody (indicated by arrowhead), quantified as a proportion of total tau, n=12. (e) Immunohistochemistry showing neurons in 28 DIV 3xTg-AD slices labelled with antibodies against total tau and tau phosphorylated at Ser202 (CP13). Scale bar is 20 μm. Data for all graphs are mean ± S.E.M. and is shown as fold change from wild-type (fold WT). *P<0.05, **P<0.01, ***P<0.001

The 3xTg-AD slice cultures were found to release a significantly larger proportion of tau under basal conditions compared with wild-types (Figure 4a). There were no significant differences in LDH release (Figure 4b). These data suggest that disease-associated forms of tau are released from healthy neurons more readily than ‘normal’ tau under basal conditions.
Neuronal stimulation increases tau release from wild-type, but not 3xTg-AD brain slice cultures. To assess the effects of neuronal stimulation on the release of normal and disease-associated tau from organotypic brain slice cultures, 50 mM KCl was applied to depolarise neurons and stimulate neuronal activity over a period of 30 min. No significant differences in LDH release between depolarised and non-depolarised wild-type and 3xTg-AD slice cultures was found, suggesting any increased tau release was not a result of increased cell death (Figure 4d). When stimulated with KCl, wild-type slice cultures showed significant increases in tau release compared with non-stimulated wild-type slice cultures (Figures 4c, P<0.05), in agreement with published data from dissociated rodent cells and in vivo in wild-type mice. In contrast, 3xTg-AD slice cultures stimulated with KCl did not demonstrate any further release of tau when compared with non-stimulated 3xTg-AD slice cultures (Figure 4d).

Bright et al. reported that secreted human tau positively feeds back to neurons to cause further neuronal activity and stimulate Aβ production over the course of 20 days. We therefore measured Aβ amounts in slice cultures stimulated with KCl for 30 min, but we found no changes in the amount of Aβ1-40 or Aβ1-42 in KCl-treated cultures in comparison with controls (Figure 4e). It is possible that longer periods of stimulation may have affected Aβ release from slices, but this was not determined here.

The presence of dephosphorylated tau at neuronal membranes is associated with the extent of tau release from brain slice cultures. Although generally considered to be cytosolic, a significant proportion of tau is associated with plasma membranes. Membrane-associated tau is predominantly dephosphorylated at serine and threonine residues. As some of the vesicles (ectosomes, exosomes) associated with tau release originate at the plasma membrane, it was of interest to investigate the proportions of tau at membranes in wild-type and 3xTg-AD slices to determine whether there is any association with tau release. Differential centrifugation was used to prepare membrane and cytosol fractions that were then immunoblotted with antibodies against tau. In 3xTg-AD slice cultures, both the membrane and cytosolic fractions contained significantly more tau than controls due to tau overexpression in this line. However, when the ratio of membrane:cytosolic tau was calculated, 3xTg-AD slices had a significantly smaller proportion of tau associated with membranes when compared with wild-type slice cultures (Figure 5a). However, the proportion of tau dephosphorylated at the Tau-1 epitope was increased in the membrane fraction of 3xTg-AD slices compared with controls (Figure 5a), an environment in which these slices also show elevated tau release relative to that of wild-type slice cultures.

Membrane and cytosolic fractions were next prepared from wild-type and 3xTg-AD slice cultures at 28 DIV treated with vehicle or 50 mM KCl to induce depolarisation. In both wild-
type and 3xTg-AD slice cultures treated with KCl, the ratio of total tau present in the membrane fraction relative to the cytosolic fraction did not differ from control treatment (Figure 5b). However, in wild-type slice cultures treated with KCl, the amount of membrane-associated tau dephosphorylated at the Tau-1 epitope was significantly increased compared with control treatment (Figure 5b), indicating an increased association of dephosphorylated tau with membranes following neuronal stimulation, conditions under which tau release was increased.

In contrast, in 3xTg-AD slice cultures treated with KCl, no changes in membrane-associated tau dephosphorylated at Tau-1 were observed (Figure 5b), conditions under which tau release is also not increased above basal levels. Taken together, these data suggest that conditions leading to an increased pool of dephosphorylated tau at membranes are associated with elevated tau release from slice cultures. In addition, these data further suggest that differences in the effect of neuronal stimulation on tau release from tissues containing normal or disease-associated tau might be related to the subcellular localisation of pools of dephosphorylated tau.

The cleavage of tau is a post-translational modification, which can affect tau function, with some fragments acting as seeds which promote tau aggregation, altered tau clearance, and, in vivo, changes in cognition and motor ability. Tau cleaved at both its N- and C-termini has been detected in AD brain. Currently, no consensus exists on whether intact, N-terminally or C-terminally truncated tau is the species of tau that propagates. Endogenous tau released under basal conditions from primary cortical rat neurons is predominantly full length, although some truncated species have been identified together with full-length tau. However, others show that only C-terminally truncated forms of endogenous tau are
secreted from unstimulated human and rodent neurons. In contrast, pathological extracellular tau in a rat model of tauopathy contains tau lacking the C terminus but containing the N terminus, and C-terminally truncated tau is released from AD synaptosomes. In addition, exogenously expressed hyperphosphorylated tau secreted from non-neuronal cells was demonstrated to be C-terminally cleaved.

To determine which species of tau are associated with membranes, the membrane fractions prepared from 28 DIV wild-type and 3xTg-AD slice cultures were immunoblotted with primary antibodies directed against the N terminus (TP007) and C terminus (TP70) of tau. Membranes of both wild-type and 3xTg-AD slice cultures contain predominantly full-length tau species of 50–64 kDa with intact N- and C-termini (Figure 5c). However, some smaller tau species of approximately 35–40 kDa and 28–30 kDa were detected by the TP007 and TP70 antibodies, respectively, indicating that some C-terminally and N-terminally truncated tau species are also present at membranes in both wild-type and 3xTg-AD slices.

There were no marked differences in the tau species detected between genotypes, indicating that phosphorylation or conformation of tau is likely more important for determining the dynamics of tau release from these slice cultures. Finally, to confirm the stringency of the fractionation, cytosolic and membrane preparations were probed for membrane-associated flotillin and cytosolic α-tubulin (Figure 5d). As expected, flotillin-1 was primarily localised in the membrane fraction, whereas α-tubulin was enriched in the cytosol.

**Discussion**

The results presented show for the first time that slice cultures from 3xTg-AD mice show progressive and accelerated development of AD-like alterations in APP, tau and synaptic proteins that mirror pathology development in 3xTg-AD mice in vivo and human AD. In particular, we show the presence of highly phosphorylated and higher molecular weight tau species in 3xTg-AD slices relative to age-matched wild-type controls. Indeed, higher phosphorylation of tau was found in...
slices compared with in vivo. This appears to be a common phenomenon in primary and slice culture models that is likely to result from the stress of culture preparation and/or the presence of medium components that can affect tau phosphorylation signalling pathways, including insulin, glutamate and horse serum. Using this culture system as a means to probe the effect of pathological tau alterations on its pattern of release, we show...
that 3xTg-AD slices release almost two-fold the amount of tau released by wild-type slice cultures in basal conditions, after normalising against total amounts expressed in 3xTg-AD slices. It should be noted that it was not possible to account for possible differences in tau localisation or association with membrane-associated vesicles in these experiments. Over-expression of tau has previously been shown to result in release of highly phosphorylated tau from cells, often in association with exosomes and/or ectosomes. In agreement with our work, tau species at the membrane have previously been identified as being predominantly dephosphorylated at serine and threonine residues when compared with cytosolic tau, and increased phosphorylation of tau, particularly at N-terminal residues, reduces its association with the membrane. Taken together, this suggests that these largely dephosphorylated species of tau may be awaiting secretion, as it has been demonstrated that both physiological and pathological extra-cellular tau species are predominantly dephosphorylated compared with species found intracellularly. It remains to be determined which species of tau are released by wild-type and 3xTg-AD slice cultures, and the precise mechanisms by which they are released.

Stimulating neuronal activity with KCl was shown here to significantly increase tau release from wild-type slice cultures, but not to stimulate any further increases in tau release from 3xTg-AD slice cultures. Increased release of tau after neuronal depolarisation has previously been shown in both wild-type rat primary cortical neurones and in vivo in wild-type mice. The reasons why KCl does not stimulate further tau release from 3xTg-AD slices are not yet identified, but may be a result of saturation of synaptic activity in 3xTg-AD slices as Aβ is known to cause increased cellular hypexcitability.

Similarly, Aβ has been shown to accelerate the propagation of tau in vivo. Therefore, it is conceivable that increased synaptic activity in the 3xTg-AD slices, reflective of conditions in AD brain, underlies the differences in tau release observed here following neuronal stimulation. However, increased tau release was found to occur upon KCl depolarisation of synaptosomes isolated from human AD, but not control, brain, in apparent disagreement with the data presented here. In this context, it is worth remembering that 3xTg-AD mice express P301L FTLD-tau and tau-associated neurodegeneration appears to differ in AD and FTLD-tau. Synapse and cell loss is more abundant in FTLD despite the number of NFTs being markedly less than those found in affected regions of AD. Thus, it is important to replicate these findings using a mouse model that overexpresses wild-type human tau such as the htau or Tau3S lines.

It should also be noted that Sokolow et al. measured tau release only from synapses, as compared with the integrated and functionally connected neural cells present in slice cultures. It is possible that the increased phosphorylation of tau in 3xTg-AD slices changes its subcellular distribution such that an increased pool of tau is docked at membranes in readiness for release, and this cannot be further increased by neuronal stimulation. In partial support of this idea, increased tau release upon KCl treatment of wild-type slices was associated with increased amounts of membrane-associated dephosphorylated tau. This might therefore argue that both physiological and pathological tau release occur, at least in part, via a common mechanism that involves accumulation of dephosphorylated tau at membranes. There were no changes in the amounts of dephosphorylated tau at membranes on KCl stimulation of 3xTg-AD slices, conditions under which no elevated tau release was observed.

The data presented here demonstrate that organotypic brain slice cultures from 3xTg-AD mice rapidly develop AD-relevant disease features and can be used as a model in vitro system to study some aspects of both tau and Aβ pathology. In addition, we demonstrate that slice cultures are an ideal model with which to investigate the processes associated with the propagation of tau in AD.

**Materials and Methods**

All materials were obtained from Sigma (Poole, Dorset, UK) unless otherwise stated.

**Organotypic brain slice culture.** Organotypic brain slice cultures were prepared from postnatal day 8–9 3xTg-AD and background control wild-type mice as previously described. Culture medium was changed every 2–3 days. The slices were treated after 28 days in culture.

**Cell death assays.** Cytotoxicity was evaluated by measuring lactate dehydrogenase (LDH) in culture medium using Cytotox 96 assay kits (Promega, Madison, WI, USA) according to the manufacturer’s directions. LDH content in medium and lysed slice cultures was measured to determine the total LDH content. Optical density was measured at 492 nm (Wallac 1420 Victor3 plate reader, PerkinElmer, Waltham, MA, USA). LDH release from slice cultures was calculated as a percentage of total LDH in each well.

**Preparation of slice culture lysates for western blotting.** After treatments, the medium was removed and the slices were washed in ice-cold phosphate-buffered saline (PBS) followed by lysis in extra strong lysis buffer (10 mM Tris-HCl (pH 7.5), 0.5% (w/v) sodium dodecyl sulphate (SDS), 20 mM sodium deoxycholate, 1% (v/v) Triton X-100, 75 mM sodium chloride, 10 mM ethylenediaminetetraacetic acid (EDTA), 2 mM sodium orthovanadate, 1.25 mM sodium fluoride and protease inhibitor cocktail for mammalian tissues (Roche Diagnostics, Burgess Hill, UK)), and centrifugation at 16 000 g for 20 min at 4 °C. The protein concentration of supernatants was measured using a BCA protein assay kit (Pierce Endogen, Rockford, USA) and the samples were standardised to equal protein concentration before being analysed by SDS-PAGE.

**Subcellular fractionation.** Cytosol and membrane fractions were prepared as previously described. Briefly, the cells were scraped into hypotonic buffer (10 mM sodium bicarbonate containing 20 mg/ml deoxyribonuclease I, 1 mM sodium orthovandate and Complete protease inhibitor cocktail (Roche, Mannheim, Germany)) and disrupted by sonication (five strokes with probe sonicator) on ice. The lysates were centrifuged at 720 x g for 5 min at 4 °C, to remove unbroken
Preparation of synaptosomes. Synaptosomes were prepared as previously described. In brief, the slices were homogenised in synaptosome lysis buffer (10 mM Tris-HCl pH 7.4, containing 0.32 M sucrose, 2 mM EDTA, 1 mM Complete protease inhibitor cocktail (Roche, Mannheim, Germany) and centrifuged at 10000 × g for 10 min at 4 °C to remove cell nuclei and debris. The supernatant (‘total fraction’) was then centrifuged at 100 000 × g for 20 min at 4 °C. The final supernatant (‘non-synaptosomal’) was mixed with Laemmli sample buffer and the pellet (‘synaptosomal fraction’) was resuspended in the same buffer.

Tau ELISA. The slice culture medium was replaced with Hank’s Balanced Salt Solution (Life Technologies Ltd, Paisley, UK). The slices were treated with the indicated compounds diluted in HBSS. HBSS was collected from neurons and centrifuged at 12 000 g for 10 min at 4 °C to remove cell debris. Tau content in HBSS was determined by ELISA using a combination of a polyclonal tau primary antibody (Dako, Ely, UK; cat #A0024 RRID:AB_10013724) and mouse monoclonal total tau antibody (BT2, Fisher Scientific, Loughborough, UK; cat #MN1010 RRID:AB_10975238) according to methods adapted from ref. 14. In brief, 96-well Nunc Maxi Sorp plates were coated with 2 μg/ml BT2 for 8 days at 4 °C with shaking. Starting blocking buffer (Thermo Scientific Ltd, Loughborough, UK) was added for 5 h at ambient temperature with shaking, followed by application of conditioned HBSS from slice cultures overnight at 37 °C. Following washing, the capture antibody (Dako) was added and incubated overnight at ambient temperature with shaking. Secondary antibody (horseradish peroxidase (HRP)-labelled anti-rabbit IgG (GE Healthcare, Little Chalfont, UK)) was added for 1 h at ambient temperature with shaking and a stabilised chromogen TMB substrate solution (Thermo Scientific Ltd, Loughborough, UK) was added for detection. Absorbance was read at 450 nm with a Wallac 1420 Victor® multilabel plate reader (PerkinElmer).

Aβ ELISA. Quantification of Aβ/40 and Aβ/42 in slice lysates was performed using ELISA kits from Invitrogen (Paisley, UK) (Aβ/40 ELISA KH33481; Aβ/42 ELISA KH33442) as we have previously described.

SDS-PAGE and immunoblotting. A total 5–20 μg protein was separated on 10% or 12% (w/v) SDS-PAGE gels and electrophoretically transferred to nitrocellulose membrane, as we have described previously. White lanes separating lanes in some immunoblots indicate removal of portions of the blot for clarity and/or splicing together of distinct blots. The following primary antibodies were used for western blotting. Total tau (rabbit IgG; Dako Ltd.; cat #A0024 RRID:AB_10013724); mouse monoclonal total tau antibody (BT2, Fisher Scientific, Loughborough, UK; cat #MN1010 RRID:AB_10975238) according to methods adapted from ref. 14. In brief, 96-well Nunc Maxi Sorp plates were coated with 2 μg/ml BT2 for 8 days at 4 °C with shaking. After blocking, the antibody (Dako) was added and incubated overnight at ambient temperature with shaking. Secondary antibody (horseradish peroxidase (HRP)-labelled anti-rabbit IgG (GE Healthcare, Little Chalfont, UK)) was added for 1 h at ambient temperature with shaking and a stabilized chromogen TMB substrate solution (Thermo Scientific Ltd, Loughborough, UK) was added for detection. Absorbance was read at 450 nm with a Wallac 1420 Victor® multilabel plate reader (PerkinElmer).

Immunohistochemistry. Organotypic brain slice cultures were fixed on their membranes in 4% PFA for 4 h and stained according to Gogolla et al. In brief, slice cultures were cut while still on their membranes and then treated as free-floating sections. The slice cultures were permeabilised for 18 h in 0.5% Triton X-100 at 4 °C and then blocked in 20% bovine serum albumin (BSA) for 4 h at RT. The slice cultures were incubated in total tau and CP13 (as above) primary antibodies overnight at 4 °C in 5% BSA, washed and then incubated in fluorophore-conjugated secondary antibodies for 4 h at RT. The slice cultures were washed a final time before mounting on slides with fluorescent mounting medium (Dako Ltd.). The slice cultures were imaged using an Eclipse Ti-E Inverted (Nikon Instruments, Kingston Upon Thames, UK) microscope using a CSU-X1 Spinning Disk Confocal and Andor ixon3 EM-CCD camera imaging system setup using a 60 Plan Apo VC N2 objective lens (Nikon Instruments).

Statistics. For slice culture and mouse brain characterisation, data were analysed by two-way ANOVA followed by Sidak’s post hoc analysis. Tau release from wild-type and 3xTg-AD slice cultures was analysed by unpaired t-test. Tau release from these cultures following treatment with KCl and vehicle was assessed using two-way ANOVA followed by Bonferroni post hoc analysis. Differences were considered statistically significant when P < 0.05. For slice cultures, n refers to each well which contained three slices.

Conflict of Interest

MSP is an employee of AstraZeneca, who part-funded this work. AMP is currently an employee of Nestle Institute of Health Science. Her contribution to this work stems from her previous position at King’s College London. The remaining authors declare no conflict of interest.

Acknowledgements. All the work performed in this manuscript was in accordance with the Animals (Scientific Procedures) Act 1986 and with the approval of ethics committees. This work was supported by funding from the National Centre for Replacement, Refinement and Reduction of Animals in Research, Alzheimer’s Research UK, the Biotechnology and Biological Sciences Research Council, AstraZeneca and the Rosetrees Charitable Trust.

Author contributions. CLC and WN contributed towards the study concept and design. CLC, KK, MAW, PW, MMH and ECP were involved in the acquisition of data. CLC, PM and WN performed the statistical analysis. CLC, PM, ECP, MAW and MMH were involved in the analysis and interpretation of the data. CLC, WN, AMP, MSP and DPH were involved in drafting of the manuscript. All the authors read and approved the final manuscript.

1. Hanger DP, Lau DH, Phillips EC, Bondulich MK, Guo T, Woodward BW et al. Intracellular and extracellular roles for tau in neurodegenerative disease. J Alzheimers Dis 2014; 40 (Suppl 1): S37–S45.
2. Clavaguera F, Hench J, Goedert M, Tohy M. Invited review: prion-like transmission and spreading of tau pathology. Neuropharmacol Appl Neurobiol 2015; 41: 47–68.
3. Lewis J, Dickson DW. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 2016; 131: 27–48.
4. Liu L, Drouet V, Wu JW, Witter MP. Small SA, Olendahl C et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 2012; 7: e31302.
5. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopkepa KJ et al. Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 2012; 73: 657–697.
6. Pooer AM, Polydoro M, Maury EA, Nicholas SB, Reddy SM, Wegmann S et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease. Acta Neuropathol Commun 2015; 3: 14.
7. Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 2012; 287: 3842–3849.
8. Arai H, Ikazu S, Tsunoda S, Medalla M, Luebke J, Haydar T et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 2015; 18: 1584–1593.
9. Polanco JC, Gotz J. No full admission for tau to the exclusive priorn club yet. EMBO J 2015; 34: 2990–2992.
10. Ahmed Z, Cooper J, Murray TK, Gam K, McLaughton E, Clarke H et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spreading of tau pathology is determined by connectivity, not proximity. Acta Neuropathol 2014; 127: 667–683.
11. Pooer AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 2013; 14: 389–394.
12. Yamada K, Holth JK, Liso F, Stewart FR, Mahan TE, Jiang H et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med 2014; 211: 387–393.
13. Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging 2015; 36: 693–709.
14. Kinnert D, Cantor A, Muratore CR, Jin M, O’Malley TT, Lee G et al. C-terminal truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death. J Neurosci 2015; 35: 10951–10965.
15. Dujardin S, Begard S, Caillerrez L, Lachaud C, Delattre D, Carrier S et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS ONE 2014; 9: e100760.
16. Simon D, Garcia-Garcia E, Gomez-Ramos A, Falcon-Perez JM, Diaz-Hernandez M, Hernandez F et al. Tau overexpression results in its secretion via membrane vesicles. Neurogenetics 2012; 13: 75–78.
17. Pouffe V, Mohamed NV, Rivest-McGraw J, Bertrand J, Lauzon M, Leclerc N. Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS ONE 2012; 7: e36873.
18. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging 2003; 24: 1063–1070.

19. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracerebral Abeta and synaptic dysfunction. Neuron 2003; 39: 609–622; 37: 673–681.

20. Humpel C. Organotypic vescibulations from whole brain adult Alzheimer mice (overexpressing amyloid-precursor-protein with the Swedish-Dutch-iaowa mutations) as a model to study clearance of beta-amyloid plaques. Front Aging Neurosci 2015; 7: 47.

21. Mewes A, Franke H, Singer D. Organotypic brain slice cultures of adult transgenic P301S mice–a novel model for tauopathy studies. PLoS ONE 2012; 7: e54017.

22. Duff K, Noble W, Gaynor K, Matsuoka Y. Organotypic slice cultures from transgenic mice as a model for tauopathy studies. J Mol Neurosci 2016; (Pt 8): 2510–2520.

23. Harwell CS, Coleman MP. Synaptophysin depletion and intraneuronal Abeta in organotypic hippocampal slice cultures from huAPP transgenic mice. Mol Neurodegeneration 2016; 11: 44.

24. Harwell CS, Coleman MP. Synaptophysin depletion and intraneuronal Abeta in organotypic hippocampal slice cultures from huAPP transgenic mice. Mol Neurodegeneration 2016; 11: 44.

25. Novotny R, Langer F, Mahler J, Skodras A, Vlachos A, Wegenast-Braun BM et al. Conversion of synthetic Abeta to in vivo active seeds and amyloid plaque formation in an hippocampal slice model. J Neurosci 2016; 36: 5084–5093.

26. Tackenberg C, Grinschnig S, Trutzel A, Santuccone AC, Frey MC, Korietzko U et al. NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis 2013; 4: e606.

27. Tang Z, Igoa E, Bercieci E, Hultenby K, Li C, Guan Z et al. mTor mediates tau localization and secretion: implication for Alzheimer’s disease. Biochim Biophys Acta 2015; 1853: 1646–1657.

28. Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Miras-Portugal MT, Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Neurodegeneration 2016; 10: 34.

29. Kuratsukaya K, Phillips EC, Crott CF, Benton G, Hughes MM, Wade MA et al. Uregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer’s disease brain. Acta Neuropathol Commun 2016; 4: 34.

30. Romberg C, Mattson MP, Mughal MR, Bussey TJ, Sakaida LM. Impaired attention in the 3xTgAD mouse model of Alzheimer’s disease: rescue by donepezil (Aricept). J Neurosci 2011; 31: 3500–3507.

31. Minami SS, Clifford TG, Hoe HS, Matsuoka Y, Rebeck GW. Fyn knock-down increases Abeta, decreases phospho-tau, and worsens spatial learning in 3xTg-AD mice. Neurobiol Aging 2012; 33: 625 e15–e24.

32. Matsuoka Y, Jouyounkhim Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF et al. A neuronal microtubule-interacting agent, NAPVSP20, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J Pharmacol Exp Ther 2008; 325: 146–153.

33. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 2008; 14: 115–119.

34. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007; 27: 3690–3692.

35. Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M et al. Assembly of tau in transgenic animals expressing P301S tau: alteration of phosphorylation and solubility. J Neurosci 2002; 33: 1498–1508.

36. Tiwari SS, Mizuno K, Ghosh A, Aziz W, Troakes C, Daoud J et al. Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss. Brain 2016; 139(Pt 10): 2751–2765.

37. Taddei-Fredare C, Senia SL, Giorgetti B, Baleiti D, Mi Stefano G, Canzoniero LM et al. Decreased presence of perforated synapses in a triple-transgenic mouse model of Alzheimer’s disease. Rejuvenation Res 2008; 11: 309–313.

38. Perez-Nieves BO, Stein TD, Tai HC, Dos-Icardo O, Scotton TC, Barrotella-Espar I et al. Dissecting synaptic traits linked to human resilience to Alzheimer’s pathology. Brain 2013; 136(Pt 11): 2510–2526.

39. Maas T, Eidenmuller J, Brandt R. Interaction of tau with the neuronal membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 2000; 275: 15733–15740.

40. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiology of Aging 2012; 33: 431 e27–431 e38.

41. Arrasaite M, Perez M, Avila J. Tau dephosphorylation at tau-1 site correlates with its association to cell membrane. Neurochem Res 2000; 25: 43–50.

42. Wang JZ, Gao X, Wang ZH. The physiology and pathology of microtubule-associated protein tau. Essays Biochem 2014; 56: 111–123.

43. Bondulich MK, Guo T, Meehan C, Manjon J, Rodriguez Martin T, Mitchell JC et al. Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. Brain 2016; 139(Pt 6): 2290–2306.

44. Garcia-Sierra F, Mondragon-Rodriguez S, Basurto-Islas G. Truncation of tau protein and its pathological significance in Alzheimer’s disease. J Alzheimers Dis 2008; 14: 401–409.

45. Socolow S, Henkins KM, Bilousova T, Gonzalez B, Vinters HV, Miller CA et al. Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer’s disease. J Neurochem 2015; 133: 368–379.

46. Brion JP, Smith C, Couch AM, Gallo JM, Anderton BH. Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer’s disease. J Neurochem 1993; 61: 2071–2080.

47. Davis DP, Brion JP, Couch AM, Gallo JM, Hanger DP, Ladhani K et al. The phosphorylation state of the microtubule-associated protein tau as affected by glutamate, colchicine and beta-amyloid in primary rat cortical neuronal cultures. Biochem J 1995; 309(Pt 3): 941–949.

48. Clavaguera F, Bolton T, Crowther RA, Abramsky D, Frank S, Probst A et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909–913.

49. Clavaguera F, Akiu T, Fraser G, Crowther RA, Frank S, Hinch J et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA 2013; 110: 9395–9404.

50. Sanders DW, Kaufman SK, DelVos SL, Sharma AM, Mirbaha H, Li A et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neurosci 2014; 122: 1271–1288.

51. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003; 86: 582–590.

52. Glynis KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM. Dynamic changes in Alzheimer’s disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol 2004; 165: 1809–1817.

53. Vagnoni A, Perkinton MS, Gray EH, Francis PT, Noble W, Miller CC. Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates Abeta production. Hum Mol Genet 2012; 21: 2845–2854.

54. Jicha GA, Lane E, Vincent I, Olivs L Jr, Hoffmann R, Davies P. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer’s disease. J Neurochem 1997; 69: 2087–2095.

55. Gogolla N, Galimberti I, DePacea V, Caroni P. Staining protocol for organotypic hippocampal slice cultures. Nat Protoc 2006; 1: 2452–2456.

**Cell Death and Disease** is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.